title: Microscale depletion of high abundance proteins in human biofluids using IgY14 immunoaffinity resin: analysis of human plasma and cerebrospinal fluid.
abstract: Removal of highly abundant proteins in plasma is often carried out using immunoaffinity depletion to extend the dynamic range of measurements to lower abundance species. While commercial depletion columns are available for this purpose, they generally are not applicable to limited sample quantities (<20 μL) due to low yields stemming from losses caused by nonspecific binding to the column matrix and concentration of large eluent volumes. Additionally, the cost of the depletion media can be prohibitive for larger-scale studies. Modern LC-MS instrumentation provides the sensitivity necessary to scale-down depletion methods with minimal sacrifice to proteome coverage, which makes smaller volume depletion columns desirable for maximizing sample recovery when samples are limited, as well as for reducing the expense of large-scale studies. We characterized the performance of a 346 μL column volume microscale depletion system, using four different flow rates to determine the most effective depletion conditions for ∼6-μL injections of human plasma proteins and then evaluated depletion reproducibility at the optimum flow rate condition. Depletion of plasma using a commercial 10-mL depletion column served as the control. Results showed depletion efficiency of the microscale column increased as flow rate decreased, and that our microdepletion was reproducible. In an initial application, a 600-μL sample of human cerebrospinal fluid (CSF) pooled from multiple sclerosis patients was depleted and then analyzed using reversed phase liquid chromatography-mass spectrometry to demonstrate the utility of the system for this important biofluid where sample quantities are more commonly limited.
authors.affiliation: Biological Sciences Division and Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, 99352, USA, swhyung@kriss.re.kr.
authors.forename: Seok-Won
authors.initials: SW
authors.lastname: Hyung
authors.forename: Paul D
authors.initials: PD
authors.lastname: Piehowski
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Moore
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Orton
authors.forename: Athena A
authors.initials: AA
authors.lastname: Schepmoes
authors.forename: Therese R
authors.initials: TR
authors.lastname: Clauss
authors.forename: Rosalie K
authors.initials: RK
authors.lastname: Chu
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Fillmore
authors.forename: Heather
authors.initials: H
authors.lastname: Brewer
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
authors.forename: Rui
authors.initials: R
authors.lastname: Zhao
authors.forename: Richard D
authors.initials: RD
authors.lastname: Smith
mesh_terms: D000418:Albumins / Q000302:isolation & purification*; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D001798:Blood Proteins / Q000032:analysis*; D002846:Chromatography, Affinity / Q000379:methods*; D002853:Chromatography, Liquid; D006801:Humans; D009103:Multiple Sclerosis / Q000097:blood* / Q000134:cerebrospinal fluid*; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000379:methods; D053719:Tandem Mass Spectrometry / Q000379:methods
chemical_list: D000418:Albumins; D015415:Biomarkers; D001798:Blood Proteins; D020543:Proteome